MX347303B - Composiciones que comprenden celulas madre embrionarias humanas y sus derivados, metodos de uso y metodos de preparacion. - Google Patents

Composiciones que comprenden celulas madre embrionarias humanas y sus derivados, metodos de uso y metodos de preparacion.

Info

Publication number
MX347303B
MX347303B MX2008011279A MX2008011279A MX347303B MX 347303 B MX347303 B MX 347303B MX 2008011279 A MX2008011279 A MX 2008011279A MX 2008011279 A MX2008011279 A MX 2008011279A MX 347303 B MX347303 B MX 347303B
Authority
MX
Mexico
Prior art keywords
methods
factor
derivatives
cells
human embryonic
Prior art date
Application number
MX2008011279A
Other languages
English (en)
Other versions
MX2008011279A (es
Inventor
Shroff Geeta
Original Assignee
Shroff Geeta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shroff Geeta filed Critical Shroff Geeta
Publication of MX2008011279A publication Critical patent/MX2008011279A/es
Publication of MX347303B publication Critical patent/MX347303B/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48Reproductive organs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48Reproductive organs
    • A61K35/54Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0603Embryonic cells ; Embryoid bodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0603Embryonic cells ; Embryoid bodies
    • C12N5/0606Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30Hormones
    • C12N2501/31Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30Hormones
    • C12N2501/38Hormones with nuclear receptors
    • C12N2501/39Steroid hormones
    • C12N2501/392Sexual steroids

Abstract

La presente invención se refiere a una composición farmacéutica para el tratamiento de enfermedades, trastornos o condiciones, caracterizad porque comprende una cantidad terapéuticamente eficaz de células madre embrionarias humanas (hES) y/o sus derivados están libres de productos animales no humanos, células alimentadoras, factores de crecimiento, factor inhibidor de leucemia, factor de crecimiento de fibroblastos, suplementos vitamínicos, factor de Steel asociado a membrana, factor de Steel soluble y medios acondicionados, en donde las células hEs y/o sus derivados están suspendidos en una solución biocompatible farmacéuticamente aceptable, en donde los derivados de células hEs se seleccionan del grupo que consiste de progenitores de células madre hematopoyéticas, progenitores de células madre neuronales, progenitores de células madre mesenquimáticas, progenitores de células madre productoras de insulina, progenitores de células madre de hepatocitos, progenitores de células madre cardiacas, progenitores de células madre epiteliales y mezclas de los mismo, y en donde las células hEs y/o sus derivados de los mismo, y en donde las células hEs y/o sus derivados se expanden por un método que comprende: a) introducir células hES y/o sus derivados en un medio de cultivo que consiste de medio esencial mínimo, una progestina y un agonista de gonadotropina coriónica humana ß b) incubar las células hEs y/o sus derivados a una temperatura de 34°C a 38°C en un ambiente de 3.5 % a 6% de dióxido de carbono durante 12 horas a 48 horas. Un método para expandir las células embrionarias, para diferenciarlas para almacenarlas, un método para preparar de dichas células, y sus médicos.
MX2008011279A 2006-03-07 2007-03-06 Composiciones que comprenden celulas madre embrionarias humanas y sus derivados, metodos de uso y metodos de preparacion. MX347303B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN582DE2006 2006-03-07
IN1500DE2006 2006-06-26
US84435006P 2006-09-14 2006-09-14
PCT/IB2007/002292 WO2007141657A2 (en) 2006-03-07 2007-03-06 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation

Publications (2)

Publication Number Publication Date
MX2008011279A MX2008011279A (es) 2008-11-25
MX347303B true MX347303B (es) 2017-04-21

Family

ID=54150153

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008011279A MX347303B (es) 2006-03-07 2007-03-06 Composiciones que comprenden celulas madre embrionarias humanas y sus derivados, metodos de uso y metodos de preparacion.

Country Status (23)

Country Link
US (9) US10545135B2 (es)
EP (11) EP1993575B1 (es)
JP (2) JP5649786B2 (es)
KR (2) KR101505202B1 (es)
CN (2) CN101420964A (es)
AP (1) AP2949A (es)
AU (1) AU2007257594B2 (es)
BR (1) BRPI0708576A2 (es)
CA (1) CA2644922C (es)
CR (1) CR10345A (es)
CU (1) CU20080161A7 (es)
DK (1) DK1993575T3 (es)
EA (1) EA027648B9 (es)
EC (1) ECSP088799A (es)
GE (1) GEP20135796B (es)
IL (1) IL193702A (es)
MA (1) MA30323B1 (es)
MX (1) MX347303B (es)
MY (1) MY154677A (es)
NO (1) NO20084181L (es)
NZ (2) NZ571127A (es)
PH (1) PH12014501028A1 (es)
WO (1) WO2007141657A2 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY154677A (en) 2006-03-07 2015-07-15 Shroff Geeta Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
ATE530638T1 (de) 2007-04-26 2011-11-15 Univ Ramot Pluripotente autologe stammzellen aus der mündlichen oder gastrointestinalen schleimhaut
JP5567476B2 (ja) * 2007-05-28 2014-08-06 モナッシュ ユニバーシティ 慢性肺疾患の治療
US20090291061A1 (en) * 2008-05-21 2009-11-26 Riordan Neil H Stem cell therapy for blood vessel degeneration
ES2556630T3 (es) * 2008-06-11 2016-01-19 Fresenius Medical Care Deutschland Gmbh Medio condicionado para células progenitoras de hígado
US20100010087A1 (en) * 2008-07-10 2010-01-14 Hong John J Methods for Inducing Stem Cell Migration and Specialization with EC-18
JP2012508584A (ja) * 2008-11-14 2012-04-12 ヴィアサイト,インコーポレイテッド ヒト多能性幹細胞由来膵臓細胞のカプセル化
GB201111244D0 (en) * 2011-06-30 2011-08-17 Konink Nl Akademie Van Wetenschappen Knaw Culture media for stem cells
US8377432B2 (en) * 2009-09-02 2013-02-19 Khay-Yong Saw Method and composition for neochondrogenesis
US8741649B2 (en) 2009-09-04 2014-06-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for enhancing genome stability and telomere elongation in embryonic stem cells
US20120201791A1 (en) * 2009-10-15 2012-08-09 Tai June Yoo Methods of treating diseases or conditions using mesenchymal stem cells
WO2011070974A1 (ja) * 2009-12-07 2011-06-16 国立大学法人名古屋大学 脂肪組織由来間葉系幹細胞を含有する、前立腺癌治療用細胞製剤
WO2011127113A1 (en) * 2010-04-08 2011-10-13 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
WO2011145110A1 (en) 2010-05-15 2011-11-24 Subhadra Dravida A novel cord blood plasma nutrient formulation and a method for the preparation thereof
AU2011326767B2 (en) * 2010-11-10 2016-02-11 Prokidney Injectable formulations for organ augmentation
FR2986537B1 (fr) * 2012-02-07 2014-03-28 Oreal Procede d'evaluation d'actif(s) apte(s) a preserver la fonctionnalite des cellules souches epitheliales
CA2870466A1 (en) * 2012-04-16 2013-10-24 The Regents Of The University Of California Ocular therapeutics using embryonic stem cell microvesicles
WO2014089121A2 (en) * 2012-12-03 2014-06-12 Thomas Ichim Retrograde delivery of cells and nucleic acids for treatment of cardiovascular diseases
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
WO2014116786A1 (en) * 2013-01-25 2014-07-31 Zietchick Research Institute,Llc Use of human chorionic gonadotropin to treat cerebral palsy and/or its co-morbidities
CN103961373A (zh) 2013-02-04 2014-08-06 西比曼生物科技(上海)有限公司 异体间质血管层细胞和异体间充质祖细胞在预防或治疗骨性关节炎中的应用
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
ITMI20130513A1 (it) * 2013-04-05 2014-10-06 Euroclone S P A Metodo diagnostico per patologie autoimmuni del fegato
CA2949171A1 (en) 2014-05-16 2015-11-19 Koninklijke Nederlandse Akademie Van Wetenschappen Improved culture method for organoids
KR101686315B1 (ko) 2015-01-09 2016-12-13 이화여자대학교 산학협력단 편도 유래 중간엽 줄기세포로부터 슈반 세포의 분화 방법
KR102036029B1 (ko) 2015-03-11 2019-10-24 이화여자대학교 산학협력단 골수 부전 예방 또는 치료용 조성물
KR20160109356A (ko) 2015-03-11 2016-09-21 이화여자대학교 산학협력단 자가 면역 질환 예방 또는 치료용 조성물
KR20160109358A (ko) 2015-03-11 2016-09-21 이화여자대학교 산학협력단 면역 질환 예방 또는 치료용 조성물
KR101885122B1 (ko) 2015-03-26 2018-09-11 이화여자대학교 산학협력단 분화촉진 및 지속형 스페로이드 형태의 편도 유래 줄기세포의 배양 방법
DK3303564T3 (da) 2015-06-01 2022-04-04 Memorial Sloan Kettering Cancer Center Fremgangsmåder til in vitro-differentiering af midthjerne-dopamin-(mda)-neuroner
KR20180105236A (ko) 2016-02-05 2018-09-27 메모리얼 슬로안-케터링 캔서 센터 줄기 세포-유래 외배엽 계통 전구체의 분화 방법
CN105749254A (zh) * 2016-02-28 2016-07-13 深圳爱生再生医学科技有限公司 用于治疗血管性痴呆的干细胞制剂及其制备方法和应用
GB201603569D0 (en) 2016-03-01 2016-04-13 Koninklijke Nederlandse Akademie Van Wetenschappen Improved differentiation method
EP3464567A4 (en) 2016-05-27 2020-01-08 Memorial Sloan Kettering Cancer Center METHODS FOR DIFFERENTIATION OF STEM CELL-DERIVED PROPERTIES
US20180242590A1 (en) * 2016-09-23 2018-08-30 Peter Friedman Compositions and methods for treating citrus plants infected with bacteria and for promoting general agricultural health
CN106177918A (zh) * 2016-09-30 2016-12-07 广州赛莱拉干细胞科技股份有限公司 一种间充质干细胞注射液及其制备方法和应用
KR102208889B1 (ko) * 2017-01-31 2021-01-27 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 다능성줄기세포의 분화 제어 방법
WO2019040790A1 (en) 2017-08-23 2019-02-28 Merakris Therapeutics, Llc COMPOSITIONS CONTAINING AMNIOTIC COMPONENTS AND METHODS FOR THEIR PREPARATION AND USE
KR102130493B1 (ko) 2018-07-11 2020-07-06 이화여자대학교 산학협력단 건선 예방 또는 치료용 조성물
KR102089476B1 (ko) 2018-07-11 2020-03-16 이화여자대학교 산학협력단 피부 염증 질환 예방 또는 치료용 조성물
KR20190120141A (ko) 2019-10-16 2019-10-23 이화여자대학교 산학협력단 골수 부전 예방 또는 치료용 조성물
KR20210119766A (ko) * 2020-03-25 2021-10-06 서울대학교병원 인간 배아줄기세포 유래 중간엽 줄기세포를 포함하는 망막색소변성의 예방 또는 치료용 약학적 조성물
CN117500916A (zh) 2021-04-16 2024-02-02 博恩赛尔公司 制备、扩增和纯化中脑多巴胺能祖细胞的方法
CN113116933A (zh) * 2021-04-26 2021-07-16 河北医科大学第四医院 一种防治糖尿病足的干细胞组合物及其应用

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744347A (en) 1987-01-16 1998-04-28 Ohio University Edison Biotechnology Institute Yolk sac stem cells and their uses
JP2740320B2 (ja) 1988-08-04 1998-04-15 アムラド・コーポレイション・リミテッド 胚幹細胞のインビトロ増殖
US5256560A (en) 1988-10-07 1993-10-26 University Of Saskatchewan Primitive cell colony stimulating factors and lymphohematopoietic progenitor cells
US5411883A (en) 1989-12-26 1995-05-02 Somatix Therapy Corporation Proliferated neuron progenitor cell product and process
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5840580A (en) 1990-05-01 1998-11-24 Becton Dickinson And Company Phenotypic characterization of the hematopoietic stem cell
US5622853A (en) 1990-05-01 1997-04-22 Becton Dickinson And Company T lymphocyte precursor
ATE181746T1 (de) 1990-09-10 1999-07-15 Takeda Chemical Industries Ltd Menschlicher rezeptor für luteinisierendes hormon und choriongonadotropin
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US6410320B1 (en) 1992-03-02 2002-06-25 The University Of Michigan Method and compositions for isolation and growth of kidney tubule stem cells, in vitro kidney tubulogenesis and ex vivo construction of renal tubules
AU658065B2 (en) 1992-03-23 1995-03-30 Nexell Therapeutics Inc. (In vitro)-derived human neutrophil precursor cells
WO1994000484A1 (en) 1992-06-22 1994-01-06 Young Henry E Scar inhibitory factor and use thereof
US5589376A (en) 1992-07-27 1996-12-31 California Institute Of Technology Mammalian neural crest stem cells
US5453357A (en) 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5690926A (en) 1992-10-08 1997-11-25 Vanderbilt University Pluripotential embryonic cells and methods of making same
SG86980A1 (en) 1992-11-16 2002-03-19 Applied Immunesciences Pluripotential quiescent stem cell population
DE4240635C2 (de) 1992-12-03 1997-07-10 Lothar Prof Dr Kanz Vermehrung hämatopoetischer Vorläuferzellen ex vivo sowieZusammensetzungen hämatopoetischer Wachstumsfaktoren
AU685506B2 (en) 1993-08-25 1998-01-22 Systemix, Inc. Method for producing a highly enriched population of hematopoietic stem cells
US5453457A (en) 1993-11-12 1995-09-26 Bayer Corporation Gamma-radiation-resistant polycarbonate composition
US5972627A (en) 1994-06-15 1999-10-26 Systemix, Inc. Method of purifying a population of cells enriched for dendritic and/or lymphoid progenitors and populations of cells obtained thereby
US5650317A (en) 1994-09-16 1997-07-22 Michigan State University Human breast epithelial cell type with stem cell and luminal epithelial cell characteristics
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US5914268A (en) 1994-11-21 1999-06-22 National Jewish Center For Immunology & Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5874301A (en) 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5821108A (en) 1995-04-07 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Enrichment for a thymocyte subset having progenitor cell activity using c-kit as a selection marker
US5876956A (en) 1995-05-15 1999-03-02 Johns Hopkins University School Of Medicine Methods for identification or purification of cells containing an enzymatic intracellular marker
US5908782A (en) 1995-06-05 1999-06-01 Osiris Therapeutics, Inc. Chemically defined medium for human mesenchymal stem cells
US6517872B1 (en) 1995-06-12 2003-02-11 Yeda Research And Development Co., Ltd. FGFR3 as a marker for mesenchymal skeletal progenitor cells
US5753505A (en) 1995-07-06 1998-05-19 Emory University Neuronal progenitor cells and uses thereof
GB9514816D0 (en) 1995-07-19 1995-09-20 Ucli Ltd Substances and their medical use
US5858782A (en) 1995-11-13 1999-01-12 Regents Of The University Of Michigan Functional human hematopoietic cells
US5997871A (en) 1996-06-24 1999-12-07 University Of Maryland Biotechnology Insitute Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin
US6969608B1 (en) 1996-08-26 2005-11-29 Mcgill University Pharmaceuticals containing multipotential precursor cells from tissues containing sensory receptors
US6890724B2 (en) 1996-09-06 2005-05-10 California Institute Of Technology Methods and compositions for neural progenitor cells
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
CA2216439A1 (en) 1996-09-25 1998-03-25 Derek Van Der Kooy Pharmaceuticals containing retinal stem cells
WO1998030679A1 (en) 1997-01-10 1998-07-16 Life Technologies, Inc. Embryonic stem cell serum replacement
US6090622A (en) 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
US6331406B1 (en) 1997-03-31 2001-12-18 The John Hopkins University School Of Medicine Human enbryonic germ cell and methods of use
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
US6734015B1 (en) 1997-07-04 2004-05-11 University Of Utah Research Foundation Isolation of lineage-restricted neuronal precursors
US6908763B1 (en) 1997-08-22 2005-06-21 The Board Of Trustees Of The Leland Stanford Junior University Mammalian common lymphoid progenitor cell
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6245757B1 (en) 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
AU1197699A (en) 1997-10-23 1999-05-10 Geron Corporation Methods and materials for the growth of primate-derived primordial stem cells
EP1034288A4 (en) 1997-12-04 2002-11-27 Univ Duke METHODS FOR INSULATION AND USE OF CD7 + CD34-LIN HEMATOPOETIC CELLS
EP1060242A4 (en) 1998-01-23 2003-09-17 Imclone Systems Inc PURIFIED POPULATIONS OF STEM CELLS
AUPP244498A0 (en) * 1998-03-18 1998-04-09 Medvet Science Pty. Ltd. Keratinocyte stem cells
US6812027B2 (en) 1998-03-25 2004-11-02 Cornell Research Foundation, Inc. Discovery, localization, harvest, and propagation of an FGF2 and BDNF-responsive population of neural and neuronal progenitor cells in the adult human forebrain
US6835567B1 (en) 1998-04-14 2004-12-28 Signal Pharmaceuticals, Inc. PNS cell lines and methods of use therefor
ATE368731T1 (de) 1998-05-29 2007-08-15 Osiris Therapeutics Inc Menschliche cd45+ und/oder fibroblasten+ mesenchymale stammzellen
US6129911A (en) 1998-07-10 2000-10-10 Rhode Island Hospital, A Lifespan Partner Liver stem cell
US6913925B1 (en) 1998-08-12 2005-07-05 Signal Pharmaceuticals Llc Human mesencephalon cell lines and methods of use therefor
DE19837438A1 (de) 1998-08-18 2000-02-24 Biotechnolog Forschung Gmbh Rekombinante Humanzelle für Knochen- und Knorpelzellbildung
US6767737B1 (en) 1998-08-31 2004-07-27 New York University Stem cells bearing an FGF receptor on the cell surface
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
WO2000035464A1 (fr) 1998-12-16 2000-06-22 Tsentr Embrionalnykh Tkanei 'emcell' Procede permettant de soigner des personnes a l'aide de suspensions cellulaires de tissus embryonnaires
BR0008468A (pt) 1999-02-24 2002-02-05 Novo Nordisk As Método para fertilização humana in vitro, uso de um hormÈnio hipotalânico e/ou hormÈnio pituitário ou de um agonista ou antagonista do mesmo ou de um derivado ativo do mesmo, kit farmacêutico em forma de dosagem única, e, qualquer novo aspecto ou combinação de aspectos
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
WO2000065068A1 (en) 1999-04-23 2000-11-02 Ceptyr, Inc. Dsp-10 dual-specificity map kinsase phosphatase
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6761883B2 (en) 1999-06-29 2004-07-13 The Board Of Trustees Of The Leland Stanford Junior University Mammalian myeloid progenitor cell subsets
DE60036470T2 (de) 1999-06-29 2008-06-19 The Board Of Trustees Of The Leland Stanford Junior University, Palo Alto Untereinheiten von myeloid-progenitorzellen von säugern
US6872389B1 (en) 1999-07-08 2005-03-29 Rhode Island Hospital Liver stem cell
US6043235A (en) 1999-07-21 2000-03-28 Research Triangle Institute 11β-aryl-17, 17-spirothiolane-substituted steroids
WO2002064748A2 (en) 2001-02-14 2002-08-22 Furcht Leo T Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
WO2001019379A2 (en) 1999-09-14 2001-03-22 Children's Medical Center Corporation, The Methods for treating muscular dystrophy with bone marrow cells
WO2001019966A2 (en) * 1999-09-14 2001-03-22 Children's Medical Center Corporation, The Isolation of muscle-derived stem cells and uses therefor
US20030082155A1 (en) 1999-12-06 2003-05-01 Habener Joel F. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
US6753153B2 (en) 1999-12-13 2004-06-22 The Scripps Research Institute Markers for identification and isolation of pancreatic islet α and β progenitors
US6416999B1 (en) 2000-04-07 2002-07-09 Raven Biotechnologies, Inc. Human Müllerian duct-derived epithelial cells and methods of isolation and uses thereof
US6436704B1 (en) 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
US20020005205A1 (en) * 2000-04-25 2002-01-17 Barry Francis P. Joint repair using mesenchymal stem cells
NL1017973C2 (nl) 2000-05-10 2002-11-08 Tristem Trading Cyprus Ltd Inrichting.
US6936281B2 (en) 2001-03-21 2005-08-30 University Of South Florida Human mesenchymal progenitor cell
AU785428B2 (en) * 2000-08-30 2007-05-17 Maria Biotech Co., Ltd Human embryonic stem cells derived from frozen-thawed embryo
US20040071665A1 (en) 2000-09-05 2004-04-15 Yong-Fu Xiao Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal
US6458588B1 (en) 2001-01-31 2002-10-01 The General Hospital Corporation Renal stem cells and uses thereof
US6852532B2 (en) 2001-03-21 2005-02-08 University Of Utah Research Foundation Method of isolating human neuroepithelial precursor cells from human fetal tissue
WO2002079457A1 (en) * 2001-03-29 2002-10-10 Ixion Biotechnology, Inc. Method for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway
US20030017587A1 (en) 2001-07-18 2003-01-23 Rader William C. Embryonic stem cells, clinical applications and methods for expanding in vitro
DE10139783C1 (de) * 2001-08-14 2003-04-17 Transtissue Technologies Gmbh Zellzusammensetzungen zur Behandlung von Osteoarthrose, sowie Verfahren zu deren Herstellung
US7527974B2 (en) * 2001-11-06 2009-05-05 Shanghai Second Medical University Embryonic stem cells derived from human somatic cell—rabbit oocyte NT units
EP1442115B9 (en) 2001-11-15 2009-12-16 Children's Medical Center Corporation Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof
JP2005510232A (ja) 2001-11-26 2005-04-21 アドバンスド セル テクノロジー、インク. 再プログラムされたヒト体細胞核ならびに自系および同系なヒト幹細胞の製造および使用方法
WO2003077865A2 (en) 2002-03-15 2003-09-25 Baxter International Inc. Methods and compositions for directing cells to target organs
US20040009589A1 (en) * 2002-03-26 2004-01-15 Shulamit Levenberg Endothelial cells derived from human embryonic stem cells
US7285415B2 (en) * 2002-07-11 2007-10-23 The Regents Of The University Of California Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
ATE536405T1 (de) * 2002-07-25 2011-12-15 Scripps Research Inst Hämatopoetische stammzellen und verfahren zur behandlung von neovaskulären augenerkrankungen damit
HK1055058A2 (en) 2002-10-11 2003-12-05 Ligand Pharm Inc 5-CYCLOALKENYL 5H-CHROMENO[3,4-f]QUINOLINE DERIVATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS
CA2501833A1 (en) 2002-10-11 2004-04-22 Ligand Pharmaceuticals Incorporated 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5h-chromeno[3,4-f]quinolines as selective progesterone receptor modulator compounds
WO2004032881A2 (en) * 2002-10-11 2004-04-22 Novocell, Inc. Implantation of encapsulated biological materials for treating diseases
AU2003285172A1 (en) * 2002-11-08 2004-06-03 The Johns Hopkins University Human embryonic stem cell cultures, and compositions and methods for growing same
UA59678A (uk) 2002-11-15 2003-09-15 Національний Медичний Університет Ім. О.О. Богомольця Спосіб лікування ревматоїдного артриту
WO2004081172A2 (en) * 2003-03-12 2004-09-23 Reliance Life Sciences Pvt. Ltd. Derivation of terminally differentiated dopaminergic neurons from human embryonic stem cells
JP2007503811A (ja) 2003-08-29 2007-03-01 ウイスコンシン アラムナイ リサーチ フオンデーシヨン 霊長類胚幹細胞からの神経幹細胞、運動ニューロン及びドーパミンニューロンのinvitroでの分化の方法
WO2005047524A2 (en) 2003-11-10 2005-05-26 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
WO2005052138A1 (en) 2003-11-19 2005-06-09 Wisconsin Alumni Research Foundation Cryopreservation of pluripotent stem cells
UA71388A (uk) 2003-12-26 2004-11-15 Інститут Нейрохірургії Імені Академіка А. П. Ромоданова Академії Медичних Наук України Спосіб отримання збагаченої суспензії стовбурових нейральних клітин
WO2005065354A2 (en) 2003-12-31 2005-07-21 The Burnham Institute Defined media for pluripotent stem cell culture
GB2441530B (en) 2004-02-12 2009-09-23 Univ Newcastle Stem Cells
WO2005099758A2 (en) * 2004-04-17 2005-10-27 The Board Of Trustees The Leland Standford Junior University Injectable bioartificial tissue matrix
WO2006044204A2 (en) 2004-10-05 2006-04-27 University Of Georgia Research Foundation, Inc. Neuronal progenitors from feeder-free human embryonic stem cell culture
MY154677A (en) 2006-03-07 2015-07-15 Shroff Geeta Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation

Also Published As

Publication number Publication date
JP5649786B2 (ja) 2015-01-07
EP2422803A3 (en) 2013-03-13
EA200801943A1 (ru) 2009-04-28
GEP20135796B (en) 2013-04-10
US20130122486A1 (en) 2013-05-16
EP2422803A2 (en) 2012-02-29
KR20140135263A (ko) 2014-11-25
NZ594639A (en) 2013-04-26
EP2422801A2 (en) 2012-02-29
EP2422794A2 (en) 2012-02-29
EP2422797A3 (en) 2013-03-20
EP2422798A3 (en) 2013-03-06
EP2422799A3 (en) 2013-03-06
EP2422799A2 (en) 2012-02-29
JP2009528834A (ja) 2009-08-13
US20140050706A1 (en) 2014-02-20
JP2014159455A (ja) 2014-09-04
US9383349B2 (en) 2016-07-05
US9482660B2 (en) 2016-11-01
MX2008011279A (es) 2008-11-25
AP2949A (en) 2014-07-31
BRPI0708576A2 (pt) 2011-05-31
CR10345A (es) 2009-03-30
CA2644922A1 (en) 2007-12-13
EP2422795A2 (en) 2012-02-29
EA027648B9 (ru) 2018-01-31
US9134299B2 (en) 2015-09-15
EP1993575B1 (en) 2019-07-03
AU2007257594A1 (en) 2007-12-13
IL193702A0 (en) 2011-08-01
US20130122588A1 (en) 2013-05-16
US20190369088A1 (en) 2019-12-05
MY154677A (en) 2015-07-15
US20090123433A1 (en) 2009-05-14
WO2007141657A3 (en) 2008-04-24
CN101420964A (zh) 2009-04-29
EP1993575A2 (en) 2008-11-26
IL193702A (en) 2015-02-26
US20140051164A1 (en) 2014-02-20
EP2422802A3 (en) 2013-03-06
EP2422800A3 (en) 2013-03-06
KR20080106332A (ko) 2008-12-04
US20140057250A1 (en) 2014-02-27
KR101505382B1 (ko) 2015-03-23
US9488643B2 (en) 2016-11-08
US8592208B2 (en) 2013-11-26
US20140051110A1 (en) 2014-02-20
US20140057350A1 (en) 2014-02-27
DK1993575T3 (da) 2019-10-14
EP2422802A2 (en) 2012-02-29
US10545135B2 (en) 2020-01-28
EP2422801A3 (en) 2013-03-06
EP2422795A3 (en) 2013-03-13
EP2422797A2 (en) 2012-02-29
US8900861B2 (en) 2014-12-02
AU2007257594B2 (en) 2012-11-01
NZ571127A (en) 2012-01-12
CU20080161A7 (es) 2012-11-15
CN103893211A (zh) 2014-07-02
EA027648B1 (ru) 2017-08-31
KR101505202B1 (ko) 2015-03-27
NO20084181L (no) 2008-11-26
WO2007141657A2 (en) 2007-12-13
MA30323B1 (fr) 2009-04-01
AP2008004623A0 (en) 2008-10-31
CA2644922C (en) 2019-07-23
WO2007141657B1 (en) 2008-07-31
EP2422798A2 (en) 2012-02-29
EP2422800A2 (en) 2012-02-29
EP2422796A3 (en) 2013-03-13
PH12014501028A1 (en) 2016-02-22
EP2422796A2 (en) 2012-02-29
EP2422794A3 (en) 2013-03-13
ECSP088799A (es) 2008-12-30
US9804151B2 (en) 2017-10-31

Similar Documents

Publication Publication Date Title
PH12014501028A1 (en) Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
KR102388828B1 (ko) 콜로니 형성 배지 및 그 용도
KR102022538B1 (ko) 에델바이스 추출물을 포함하는 피부 재생 및 모발 성장 촉진제
KR101757827B1 (ko) 때죽나무(Styrax japonica) 추출물을 유효성분으로 포함하는 히알루로니다아제(HAase, hyaluronidase) 저해제 및 이를 포함하는 항염증 및 항알레르기 조성물
EP2977446A1 (en) Method for inducing pluripotent stem cells and pluripotent stem cells prepared by said method
UA99813C2 (ru) Композиция человеческих эмбриональных стволовых клеток или их производных, способы применения и способы получения (варианты)
KR20160006127A (ko) 줄기세포의 보관 안정성 증진용 조성물
JP6583679B2 (ja) 酵母抽出物を用いた幹細胞の未分化状態維持剤及び増殖促進剤
KR101902425B1 (ko) 치자 추출물을 포함하는 재생 촉진제
JP2016202098A (ja) マンネンタケ抽出物を用いた幹細胞の未分化状態維持剤及び増殖促進剤
EP4089164A1 (en) Composition for reinforcing function of stem cell
KR20150066224A (ko) Ycg063을 함유하는 암전이 억제용 조성물
KR101999842B1 (ko) 지방유래 줄기세포 추출물을 유효성분으로 함유하는 염증성 질환 예방 또는 치료용 조성물
KR101644964B1 (ko) 페리오스틴 유래 펩타이드를 유효성분으로 포함하는 혈관신생 촉진용 조성물
WO2005056780A3 (en) Cell culture with nm23, cell culture media comprising nm23 and therapeutic use of cells cultured in the presence of nm23.
Jayawardana et al. Protease inhibitory activity of some medicinal plants in Sri Lanka
KR101835180B1 (ko) 재조합 BTG2(B cell translocation gene 2) 단백질 및 이의 생산방법
Marasović et al. Dietary intake and antitumour preventive properties of 2, 4, 6-trifluorophenylboronic acid in mice: Some results and prospects
WO2010037826A3 (en) Method of enriching stem cells in culture
KR20220073565A (ko) 천연물 추출물 전처리 줄기세포 유래 엑소좀을 포함하는 신경질환 치료용 조성물 및 이의 용도
JP6840376B2 (ja) 幹細胞の未分化状態維持剤及び増殖促進剤
JP2015228855A (ja) 幹細胞の未分化状態維持剤及び増殖促進剤
KR20150146097A (ko) 때죽나무(Styrax japonica) 추출물을 유효성분으로 포함하는 히알루로니다아제(HAase, hyaluronidase) 저해제를 포함하는 항염증 조성물
Sheikhpour et al. 0TAntiproliferative effects 0T5T of 5T Ectoine and Hydroxyectoine 5 Ton human 0T5Tlung cancer cells. I
AU2013206647A1 (en) Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms

Legal Events

Date Code Title Description
FG Grant or registration